Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014 (2014), Article ID 730380, 9 pages
http://dx.doi.org/10.1155/2014/730380
Review Article

The Treg/Th17 Paradigm in Lung Cancer

1Department of Respiratory Medicine, The Eighth People’s Hospital of Nanning, Nanning, Guangxi 530001, China
2Department of Respiratory Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China
3Department of Respiratory Medicine, The First People’s Hospital of Nanning, Nanning, Guangxi 530022, China

Received 10 December 2013; Revised 21 March 2014; Accepted 4 April 2014; Published 29 April 2014

Academic Editor: Yi Zhang

Copyright © 2014 Min-Chao Duan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Reddy, D. Chilla, and J. Boltax, “Lung cancer screening: a review of available data and current guidelines,” Hospital Practice, vol. 39, no. 4, pp. 107–112, 2011. View at Google Scholar · View at Scopus
  3. A. J. Alberg, M. V. Brock, J. G. Ford, J. M. Samet, and S. D. Spivack, “Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 143, supplement 5, pp. e1S–e29S, 2013. View at Google Scholar
  4. J. Ellis, “The impact of lung cancer on patients and carers,” Chronic Respiratory Disease, vol. 9, no. 1, pp. 39–47, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Milara and J. Cortijo, “Tobacco, inflammation, and respiratory tract cancer,” Current Pharmaceutical Design, vol. 18, no. 26, pp. 3901–3938, 2012. View at Publisher · View at Google Scholar
  6. A. M. Houghton, “Mechanistic links between COPD and lung cancer,” Nature Reviews Cancer, vol. 13, no. 4, pp. 233–245, 2013. View at Publisher · View at Google Scholar
  7. D. R. Brenner, J. R. McLaughlin, and R. J. Hung, “Previous lung diseases and lung cancer risk: a systematic review and meta-analysis,” PLoS ONE, vol. 6, no. 3, Article ID e17479, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. D. S. O'Callaghan, D. O'Donnell, F. O'Connell, and K. J. O'Byrne, “The role of inflammation in the pathogenesis of non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 5, no. 12, pp. 2024–2036, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. S. A. Khuder, “Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis,” Lung Cancer, vol. 31, no. 2-3, pp. 139–148, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Pesch, B. Kendzia, P. Gustavsson et al., “Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case-control studies,” International Journal of Cancer, vol. 131, no. 5, pp. 1210–1219, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. M. A. Swartz, N. Iida, E. W. Roberts et al., “Tumor microenvironment complexity: emerging roles in cancer therapy,” Cancer Research, vol. 72, pp. 2473–2480, 2012. View at Publisher · View at Google Scholar
  12. D. Nelson and R. Ganss, “Tumor growth or regression: powered by inflammation,” Journal of Leukocyte Biology, vol. 80, no. 4, pp. 685–690, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Imahayashi, T. So, M. Sugaya et al., “Establishment of an immortalized T-cell line from lung cancer tissue: phenotypic and functional analyses,” International Journal of Clinical Oncology, vol. 7, no. 1, pp. 38–44, 2002. View at Google Scholar · View at Scopus
  14. A. K. Abbas, K. M. Murphy, and A. Sher, “Functional diversity of helper T lymphocytes,” Nature, vol. 383, no. 6603, pp. 787–793, 1996. View at Publisher · View at Google Scholar · View at Scopus
  15. C. T. Weaver and R. D. Hatton, “Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective,” Nature Reviews Immunology, vol. 9, no. 12, pp. 883–889, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Sallusto and A. Lanzavecchia, “Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity,” European Journal of Immunology, vol. 39, no. 8, pp. 2076–2082, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Wang, J. Xu, Q. Zhu et al., “Downregulation of IFNG in CD4+ T cells in lung cancer through hypermethylation: a possible mechanism of tumor-induced immunosuppression,” PLoS ONE, vol. 8, no. 11, Article ID e79064, 2013. View at Google Scholar
  18. N. Ito, H. Nakamura, Y. Tanaka, and S. Ohgi, “Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry,” Cancer, vol. 85, no. 11, pp. 2359–2367, 1999. View at Google Scholar
  19. E. Bettelli, T. Korn, and V. K. Kuchroo, “Th17: the third member of the effector T cell trilogy,” Current Opinion in Immunology, vol. 19, no. 6, pp. 652–657, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Steinman, “A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage,” Nature Medicine, vol. 13, no. 2, pp. 139–145, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. A. P. Ganesan, M. Johansson, B. Ruffell et al., “Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma,” The Journal of Immunology, vol. 191, no. 4, pp. 2009–2017, 2013. View at Publisher · View at Google Scholar
  22. Y. Li, Z. Y. Cao, B. Sun et al., “Effects of IL-17A on the occurrence of lung adenocarcinoma,” Cancer Biology & Therapy, vol. 12, pp. 610–616, 2011. View at Publisher · View at Google Scholar
  23. T. R. Mosmann, H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman, “Two types of murine helper T cell clone—I. Definition according to profiles of lymphokine activities and secreted proteins,” The Journal of Immunology, vol. 136, no. 7, pp. 2348–2357, 1986. View at Google Scholar · View at Scopus
  24. R. M. Anthony, L. I. Rutitzky, J. F. Urban, M. J. Stadecker, and W. C. Gause, “Protective immune mechanisms in helminth infection,” Nature Reviews Immunology, vol. 7, no. 12, pp. 975–987, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Sinigaglia, D. D'Ambrosio, and L. Rogge, “Type I interferons and the Th1/Th2 paradigm,” Developmental & Comparative Immunology, vol. 23, no. 7-8, pp. 657–663, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Gran, G.-X. Zhang, S. Yu et al., “IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: Evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination,” The Journal of Immunology, vol. 169, no. 12, pp. 7104–7110, 2002. View at Google Scholar · View at Scopus
  27. D. Vitolo, L. Ciocci, P. Ferrauti et al., “Interleukin-12-related cytokine gene expression in carcinomas of the breast, lung, and larynx: a study at tissue level,” Cancer Detection and Prevention, vol. 24, no. 5, pp. 422–434, 2000. View at Google Scholar · View at Scopus
  28. H. Echchakir, C. Asselin-Paturel, G. Dorothee et al., “Analysis of T-cell-receptor β-chain-gene usage in peripheral-blood and tumor-infiltrating lymphocytes from human non-small-cell lung carcinomas,” International Journal of Cancer, vol. 81, no. 2, pp. 205–213, 1999. View at Google Scholar
  29. R. B. Baleeiro, L. B. Anselmo, F. A. Soares et al., “High frequency of immature dendritic cells and altered in situ production of interleukin-4 and tumor necrosis factor-α in lung cancer,” Cancer Immunology, Immunotherapy, vol. 57, no. 9, pp. 1335–1345, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. X. Li, W. Shi, G. Yu et al., “Interleukin-4-590 T/C polymorphism influences the susceptibility to nonsmall cell lung cancer,” DNA and Cell Biology, vol. 31, no. 5, pp. 797–800, 2012. View at Publisher · View at Google Scholar
  31. R. Li, D. Rüttinger, R. Li, L.-S. Si, and Y.-L. Wang, “Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer,” Langenbeck's Archives of Surgery, vol. 388, no. 6, pp. 406–412, 2003. View at Publisher · View at Google Scholar
  32. S. Reppert, I. Boross, M. Koslowski et al., “A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer,” Nature Communications, vol. 2, no. 1, article 600, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Hagenbaugh, S. Sharma, S. M. Dubinett et al., “Altered immune responses in interleukin 10 transgenic mice,” Journal of Experimental Medicine, vol. 185, no. 12, pp. 2101–2110, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. D. J. Gough, D. E. Levy, R. W. Johnstone, and C. J. Clarke, “IFNγ signaling—does it mean JAK-STAT?” Cytokine & Growth Factor Reviews, vol. 19, no. 5, pp. 383–394, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. H. A. Young and J. H. Bream, “IFN-γ: recent advances in understanding regulation of expression, biological functions, and clinical applications,” Current Topics in Microbiology and Immunology, vol. 316, pp. 97–117, 2007. View at Google Scholar · View at Scopus
  36. F. El Hage, I. Vergnon, D. Grunenwald, J. C. Soria, S. Chouaib, and F. Mami-Chouaib, “Generation of diverse mutated tumor antigen-specific cytotoxic T lymphocytes in a lung cancer patient with long survival,” Oncology Reports, vol. 14, no. 3, pp. 763–769, 2005. View at Google Scholar · View at Scopus
  37. K. L. Dennis, N. R. Blatner, F. Gounari, and K. Khazaie, “Current status of interleukin-10 and regulatory T-cells in cancer,” Current Opinion in Oncology, vol. 25, no. 6, pp. 637–645, 2013. View at Publisher · View at Google Scholar
  38. M. Huang, J. Wang, P. Lee et al., “Human non-small cell lung cancer cells express a type 2 cytokine pattern,” Cancer Research, vol. 55, no. 17, pp. 3847–3853, 1995. View at Google Scholar · View at Scopus
  39. A. Wojciechowska-Lacka, M. Matecka-Nowak, E. Adamiak, J. K. Lacki, and B. Cerkaska-Gluszak, “Serum levels of interleukin-10 and interleukin-6 in patients with lung cancer,” Neoplasma, vol. 43, no. 3, pp. 155–158, 1996. View at Google Scholar · View at Scopus
  40. C. A. Stewart, H. Metheny, N. Iida et al., “Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation,” The Journal of Clinical Investigation, vol. 123, no. 11, pp. 4859–4874, 2013. View at Publisher · View at Google Scholar
  41. M. C. Fantini, C. Becker, G. Monteleone, F. Pallone, P. R. Galle, and M. F. Neurath, “Cutting edge: TGF-β induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7,” The Journal of Immunology, vol. 172, no. 9, pp. 5149–5153, 2004. View at Google Scholar · View at Scopus
  42. W. Chen and S. M. Wahl, “TGF-β: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression,” Cytokine & Growth Factor Reviews, vol. 14, no. 2, pp. 85–89, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Peck and E. D. Mellins, “Plasticity of T-cell phenotype and function: the T helper type 17 example,” Immunology, vol. 129, no. 2, pp. 147–153, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. E. M. Shevach, “CD4+CD25+ suppressor T cells: more questions than answers,” Nature Reviews Immunology, vol. 2, no. 6, pp. 389–400, 2002. View at Google Scholar · View at Scopus
  45. H. von Boehmer, “Mechanisms of suppression by suppressor T cells,” Nature Immunology, vol. 6, no. 4, pp. 338–344, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. T. L. Whiteside, “Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?” Cancer Immunology, Immunotherapy, vol. 63, no. 1, pp. 67–72, 2014. View at Publisher · View at Google Scholar
  47. L. Zhou, M. M. W. Chong, and D. R. Littman, “Plasticity of CD4+ T cell lineage differentiation,” Immunity, vol. 30, no. 5, pp. 646–655, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. D. Mucida, K. Pino-Lagos, G. Kim et al., “Retinoic acid can directly promote TGF-β-mediated Foxp3+ Treg cell conversion of naive T cells,” Immunity, vol. 30, no. 4, pp. 471–472, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. J. A. Hill, J. A. Hall, C.-M. Sun et al., “Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD4+CD44hi cells,” Immunity, vol. 29, no. 5, pp. 758–770, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Wolf, A. Schimpl, and T. Hunig, “Control of T cell hyperactivation in IL-2-deficient mice by CD4+CD25 and CD4+CD25+T cells: evidence for two distinct regulatory mechanisms,” European Journal of Immunology, vol. 31, no. 6, pp. 1637–1645, 2001. View at Google Scholar
  51. E. Y. Woo, H. Yeh, C. S. Chu et al., “Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation,” The Journal of Immunology, vol. 168, no. 9, pp. 4272–4276, 2002. View at Google Scholar · View at Scopus
  52. N. Erfani, S. M. Mehrabadi, M. A. Ghayumi et al., “Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC),” Lung Cancer, vol. 77, no. 2, pp. 306–311, 2012. View at Publisher · View at Google Scholar
  53. J. Domagała-Kulawik, G. Hoser, A. Safianowska, H. Grubek-Jaworska, and R. Chazan, “Elevated TGF-β1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer,” Archivum Immunologiae et Therapiae Experimentalis, vol. 54, no. 2, pp. 143–147, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. G. E. Carpagnano, A. Spanevello, C. Curci et al., “IL-2, TNF-α, and leptin: local versus systemic concentrations in NSCLC patients,” Oncology Research, vol. 16, no. 8, pp. 375–381, 2007. View at Google Scholar · View at Scopus
  55. E. Y. Woo, C. S. Chu, T. J. Goletz et al., “Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer,” Cancer Research, vol. 61, no. 12, pp. 4766–4772, 2001. View at Google Scholar · View at Scopus
  56. K. E. de Visser and W. M. Kast, “Effects of TGF-β on the immune system: implications for cancer immunotherapy,” Leukemia, vol. 13, no. 8, pp. 1188–1199, 1999. View at Google Scholar · View at Scopus
  57. B. Salomon, D. J. Lenschow, L. Rhee et al., “B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes,” Immunity, vol. 12, no. 4, pp. 431–440, 2000. View at Google Scholar · View at Scopus
  58. W. Chen, W. Jin, and S. M. Wahl, “Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor β (TGF-β) production by murine CD4+ T cells,” Journal of Experimental Medicine, vol. 188, no. 10, pp. 1849–1857, 1998. View at Publisher · View at Google Scholar · View at Scopus
  59. Y.-Q. Chen, H.-Z. Shi, X.-J. Qin et al., “CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 11, pp. 1434–1439, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. A. P. Ganesan, M. Johansson, B. Ruffell et al., “Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma,” The Journal of Immunology, vol. 191, no. 4, pp. 2009–2017, 2013. View at Publisher · View at Google Scholar
  61. L. Zhao, J. Yang, H. P. Wang, and R. Y. Liu, “Imbalance in the Th17/Treg and cytokine environment in peripheral blood of patients with adenocarcinoma and squamous cell carcinoma,” Medical Oncology, vol. 30, no. 1, article 461, 2013. View at Publisher · View at Google Scholar
  62. X.-J. Qin, H.-Z. Shi, J.-M. Deng, Q.-L. Liang, J. Jiang, and Z.-J. Ye, “CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion,” Clinical Cancer Research, vol. 15, no. 7, pp. 2231–2237, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. M. J. Smyth, M. W. L. Teng, J. Swann, K. Kyparissoudis, D. I. Godfrey, and Y. Hayakawa, “CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer,” The Journal of Immunology, vol. 176, no. 3, pp. 1582–1587, 2006. View at Google Scholar · View at Scopus
  64. R. P. Petersen, M. J. Campa, J. Sperlazza et al., “Tumor infiltrating FOXP3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients,” Cancer, vol. 107, no. 12, pp. 2866–2872, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. K. Shimizu, M. Nakata, Y. Hirami, T. Yukawa, A. Maeda, and K. Tanemoto, “Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 5, no. 5, pp. 585–590, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Liu, T. Zhang, J. Ye et al., “Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer,” Cancer Immunology, Immunotherapy, vol. 61, no. 10, pp. 1849–1856, 2012. View at Publisher · View at Google Scholar
  67. E. Bettelli, Y. Carrier, W. Gao et al., “Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells,” Nature, vol. 441, no. 7090, pp. 235–238, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Veldhoen, R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger, “TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells,” Immunity, vol. 24, no. 2, pp. 179–189, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. C. Dong, “TH17 cells in development: an updated view of their molecular identity and genetic programming,” Nature Reviews Immunology, vol. 8, no. 5, pp. 337–348, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. L. A. Zúñiga, R. Jain, C. Haines, and D. J. Cua, “Th17 cell development: from the cradle to the grave,” Immunological Reviews, vol. 252, no. 1, pp. 78–88, 2013. View at Publisher · View at Google Scholar
  71. I. I. Ivanov, B. S. McKenzie, L. Zhou et al., “The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells,” Cell, vol. 126, no. 6, pp. 1121–1133, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. X. O. Yang, A. D. Panopoulos, R. Nurieva et al., “STAT3 regulates cytokine-mediated generation of inflammatory helper T cells,” The Journal of Biological Chemistry, vol. 282, no. 13, pp. 9358–9363, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. P. R. Mangan, L. E. Harrington, D. B. O’Quinn et al., “Transforming growth factor-β induces development of the TH17 lineage,” Nature, vol. 441, no. 7090, pp. 231–234, 2006. View at Publisher · View at Google Scholar
  74. E. V. Acosta-Rodriguez, G. Napolitani, A. Lanzavecchia, and F. Sallusto, “Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells,” Nature Immunology, vol. 8, no. 9, pp. 942–949, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. N. J. Wilson, K. Boniface, J. R. Chan et al., “Development, cytokine profile and function of human interleukin 17-producing helper T cells,” Nature Immunology, vol. 8, no. 9, pp. 950–957, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. T. Korn, E. Bettelli, M. Oukka, and V. K. Kuchroo, “IL-17 and Th17 cells,” Annual Review of Immunology, vol. 27, pp. 485–517, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. E. Rouvier, M.-F. Luciani, M.-G. Mattei, F. Denizot, and P. Golstein, “CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus Saimiri gene,” The Journal of Immunology, vol. 150, no. 12, pp. 5445–5456, 1993. View at Google Scholar · View at Scopus
  78. M. Kawaguchi, M. Adachi, N. Oda, F. Kokubu, and S.-K. Huang, “IL-17 cytokine family,” The Journal of Allergy and Clinical Immunology, vol. 114, no. 6, pp. 1265–1273, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. M.-L. Michel, D. Mendes-da-Cruz, A. C. Keller et al., “Critical role of ROR-γt in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 50, pp. 19845–19850, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. B. Ciric, M. El-behi, R. Cabrera, G.-X. Zhang, and A. Rostami, “IL-23 drives pathogenic IL-17-producing CD8+ T cells,” The Journal of Immunology, vol. 182, no. 9, pp. 5296–5305, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. A. B. van der Waart, W. J. van der Velden, A. G. van Halteren et al., “Decreased levels of circulating IL17-producing CD161+CCR6+ T cells are associated with graft-versus-host disease after allogeneic stem cell transplantation,” PLoS ONE, vol. 7, no. 12, Article ID e50896, 2012. View at Publisher · View at Google Scholar
  82. K. Shibata, H. Yamada, M. Nakamura et al., “IFN-γ-producing and IL-17-producing γδ T cells differentiate at distinct developmental stages in murine fetal thymus,” The Journal of Immunology, vol. 192, no. 5, pp. 2210–2218, 2014. View at Publisher · View at Google Scholar
  83. M.-L. Michel, A. C. Keller, C. Paget et al., “Identification of an IL-17-producing NK1.1neg iNKT cell population involved in airway neutrophilia,” Journal of Experimental Medicine, vol. 204, no. 5, pp. 995–1001, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. C. Ramirez-Velazquez, E. C. Castillo, L. Guido-Bayardo, and V. Ortiz-Navarrete, “IL-17-producing peripheral blood CD177+ neutrophils increase in allergic asthmatic subjects,” Allergy, Asthma & Clinical Immunology, vol. 9, article 23, 2013. View at Publisher · View at Google Scholar
  85. M. Numasaki, M. Watanabe, T. Suzuki et al., “IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis,” The Journal of Immunology, vol. 175, no. 9, pp. 6177–6189, 2005. View at Google Scholar · View at Scopus
  86. Y. Carmi, G. Rinott, S. Dotan et al., “Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis,” The Journal of Immunology, vol. 186, no. 6, pp. 3462–3471, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. Q. Li, Y. Han, G. Fei, Z. Guo, T. Ren, and Z. Liu, “IL-17 promoted metastasis of non-small-cell lung cancer cells,” Immunology Letters, vol. 148, no. 2, pp. 144–150, 2012. View at Publisher · View at Google Scholar
  88. D. He, H. Li, N. Yusuf et al., “IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells,” The Journal of Immunology, vol. 184, no. 5, pp. 2281–2288, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. I. Kryczek, S. Wei, W. Szeliga, L. Vatan, and W. Zou, “Endogenous IL-17 contributes to reduced tumor growth and metastasis,” Blood, vol. 114, no. 2, pp. 357–359, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. N. Martin-Orozco, P. Muranski, Y. Chung et al., “T helper 17 cells promote cytotoxic T cell activation in tumor immunity,” Immunity, vol. 31, no. 5, pp. 787–798, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Kobold, S. Völk, T. Clauditz et al., “Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells,” Journal of Thoracic Oncology, vol. 8, no. 8, pp. 1032–1042, 2013. View at Publisher · View at Google Scholar
  92. Z. J. Ye, Q. Zhou, W. Yin et al., “Interleukin 22-producing CD4+ T cells in malignant pleural effusion,” Cancer Letters, vol. 326, no. 1, pp. 23–32, 2012. View at Publisher · View at Google Scholar
  93. D. Lejeune, L. Dumoutier, S. Constantinescu, W. Kruijer, J. J. Schuringa, and J.-C. Renauld, “Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line: pathways that are shared with and distinct from IL-10,” The Journal of Biological Chemistry, vol. 277, no. 37, pp. 33676–33682, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. F. Romerio and D. Zella, “MEK and ERK inhibitors enhance the anti-proliferative effect of interferon-α2b,” The FASEB Journal, vol. 16, no. 12, pp. 1680–1682, 2002. View at Google Scholar · View at Scopus
  95. J. J. Wu, X. D. Zhang, S. Gillespie, and P. Hersey, “Selection for TRAIL resistance results in melanoma cells with high proliferative potential,” FEBS Letters, vol. 579, no. 9, pp. 1940–1944, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. J. Y. Fang and B. C. Richardson, “The MAPK signalling pathways and colorectal cancer,” The Lancet Oncology, vol. 6, no. 5, pp. 322–327, 2005. View at Publisher · View at Google Scholar · View at Scopus
  97. K. Koyama, H. Kagamu, S. Miura et al., “Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage,” Clinical Cancer Research, vol. 14, no. 21, pp. 6770–6779, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. Z.-J. Ye, Q. Zhou, Y.-Y. Gu et al., “Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion,” The Journal of Immunology, vol. 185, no. 10, pp. 6348–6354, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. W. Zou and N. P. Restifo, “TH17 cells in tumour immunity and immunotherapy,” Nature Reviews Immunology, vol. 10, no. 4, pp. 248–256, 2010. View at Publisher · View at Google Scholar · View at Scopus
  100. N. Martin-Orozco, P. Muranski, Y. Chung et al., “T helper 17 cells promote cytotoxic T cell activation in tumor immunity,” Immunity, vol. 31, no. 5, pp. 787–798, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. Z.-J. Ye, Q. Zhou, J.-C. Zhang et al., “CD39+ regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism,” Respiratory Research, vol. 12, article 77, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. E. de Jong, T. Suddason, and G. M. Lord, “Translational mini-review series on Th17 Cells: development of mouse and human T helper 17 cells,” Clinical & Experimental Immunology, vol. 159, no. 2, pp. 148–158, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. A. Peck and E. D. Mellins, “Plasticity of T-cell phenotype and function: the T helper type 17 example,” Immunology, vol. 129, no. 2, pp. 147–153, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. S. Q. Crome, A. Y. Wang, and M. K. Levings, “Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease,” Clinical & Experimental Immunology, vol. 159, no. 2, pp. 109–119, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. E. V. Acosta-Rodriguez, L. Rivino, J. Geginat et al., “Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells,” Nature Immunology, vol. 8, no. 6, pp. 639–646, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. Z. Chen, F. Lin, Y. Gao et al., “FOXP3 and RORγt: transcriptional regulation of Treg and Th17,” International Immunopharmacology, vol. 11, no. 5, pp. 536–542, 2011. View at Publisher · View at Google Scholar · View at Scopus
  107. H. J. Koenen, R. L. Smeets, P. M. Vink, E. van Rijssen, A. M. H. Boots, and I. Joosten, “Human CD25highFoxp3pos regulatory T cells differentiate into IL-17 producing cells,” Blood, vol. 112, no. 6, pp. 2340–2352, 2008. View at Publisher · View at Google Scholar · View at Scopus
  108. L. Zhou, J. E. Lopes, M. M. W. Chong et al., “TGF-Β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function,” Nature, vol. 453, no. 7192, pp. 236–240, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. X. O. Yang, R. Nurieva, G. J. Martinez et al., “Molecular antagonism and plasticity of regulatory and inflammatory T cell programs,” Immunity, vol. 29, no. 1, pp. 44–56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. S. Hougaard, M. Krarup, P. Nørgaard, L. Damstrup, M. Spang-Thomsen, and H. Skovgaard Poulsen, “High value of the radiobiological parameter Dq correlates to expression of the transforming growth factor β type II receptor in a panel of small cell lung cancer cell lines,” Lung Cancer, vol. 20, no. 1, pp. 65–69, 1998. View at Publisher · View at Google Scholar · View at Scopus
  111. H.-S. Jeon and J. Jen, “TGF-β signaling and the role of inhibitory smads in non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 5, no. 4, pp. 417–419, 2010. View at Publisher · View at Google Scholar · View at Scopus
  112. Y. Hasegawa, S. Takanashi, Y. Kanehira, T. Tsushima, T. Imai, and K. Okumura, “Transforming growth factor-β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with non-small cell lung carcinoma,” Cancer, vol. 91, no. 5, pp. 964–971, 2001. View at Google Scholar
  113. A. B. Roberts and L. M. Wakefield, “The two faces of transforming growth factor β in carcinogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 15, pp. 8621–8623, 2003. View at Publisher · View at Google Scholar · View at Scopus
  114. N. Yosef, A. K. Shalek, J. T. Gaublomme et al., “Dynamic regulatory network controlling TH17 cell differentiation,” Nature, vol. 496, no. 7446, pp. 461–468, 2013. View at Publisher · View at Google Scholar
  115. S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, inflammation, and cancer,” Cell, vol. 140, no. 6, pp. 883–899, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, no. 7203, pp. 436–444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  117. S. Ostrand-Rosenberg, “Immune surveillance: a balance between protumor and antitumor immunity,” Current Opinion in Genetics & Development, vol. 18, no. 1, pp. 11–18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  118. D. G. DeNardo, P. Andreu, and L. M. Coussens, “Interactions between lymphocytes and myeloid cells regulate pro-versus anti-tumor immunity,” Cancer and Metastasis Reviews, vol. 29, no. 2, pp. 309–316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. S. K. Drexler and A. S. Yazdi, “Complex roles of inflammasomes in carcinogenesis,” Cancer Journal, vol. 19, no. 6, pp. 468–472, 2013. View at Publisher · View at Google Scholar